First Occurrence of Plasmablastic Lymphoma in Adenosine Deaminase-Deficient Severe Combined Immunodeficiency Disease Patient and Review of the Literature

Maddalena Migliavacca1, Andrea Assanelli2, Maurilio Ponzoni3, Roberta Pajno1, Federica Barzaghi1, Fabio Giglio2, Francesca Ferrua1,4, Marta Frittoli1, Immacolata Brigida5, Francesca Dionisio6, Roberto Nicoletti7, Miriam Casiraghi1, Maria Grazia Roncarolo1-7, Claudio Doglioni2,4, Jacopo Peccatori2, Fabio Ciceri2,4, Maria Pia Cicalese1 and Alessandro Aiuti1,4*

1 San Raffaele Telethon Institute for Gene Therapy (SR-TIGET), Pediatric Immunohematology and Bone Marrow Transplantation Unit, Scientific Institute San Raffaele (IRCCS), Milan, Italy, 2 Hematology and Bone Marrow Transplantation Unit, Scientific Institute San Raffaele (IRCCS), Milan, Italy, 3 Pathology Unit, Scientific Institute San Raffaele (IRCCS), Milan, Italy, 4 Vita-Salute San Raffaele University, Milan, Italy, 5 San Raffaele Telethon Institute for Gene Therapy (SR-TIGET), Scientific Institute San Raffaele (IRCCS), Milan, Italy, 6 Department of Radiology, Scientific Institute San Raffaele (IRCCS), Milan, Italy, 7 Division of Stem Cell Transplantation and Regenerative Medicine, Department of Pediatrics, Institute for Stem Cell Biology and Regenerative Medicine, Stanford School of Medicine, Stanford, CA, United States

Adenosine deaminase-deficient severe combined immunodeficiency disease (ADA-SCID) is a primary immune deficiency characterized by mutations in the ADA gene resulting in accumulation of toxic compounds affecting multiple districts. Hematopoietic stem cell transplantation (HSCT) from a matched donor and hematopoietic stem cell gene therapy are the preferred options for definitive treatment. Enzyme replacement therapy (ERT) is used to manage the disease in the short term, while a decreased efficacy is reported in the medium-long term. To date, eight cases of lymphomas have been described in ADA-SCID patients. Here we report the first case of plasmablastic lymphoma occurring in a young adult with ADA-SCID on long-term ERT, which turned out to be Epstein–Barr virus associated. The patient previously received infusions of genetically modified T cells. A cumulative analysis of the eight published cases of lymphoma from 1992 to date, and the case here described, reveals a high mortality (89%). The most common form is diffuse large B-cell lymphoma, which predominantly occurs in extra nodal sites. Seven cases occurred in patients on ERT and two after haploidentical HSCT. The significant incidence of immunodeficiency-associated lymphoproliferative disorders and poor survival of patients developing this complication highlight the priority in finding a prompt curative treatment for ADA-SCID.

Keywords: adenosine deaminase-deficient severe combined immunodeficiency disease, lymphoma, plasmablastic lymphoma, primary immunodeficiency, gene therapy, gene therapy for rare diseases, review of literature

INTRODUCTION

The development of immunodeficiency-associated lymphoproliferative disorders (IALDs), especially related to Epstein–Barr virus (EBV), is a life-threatening phenomenon. The incidence of IALD in primary immune deficiencies due to various gene defects ranges from 0.7 to 18% of patients (1). Adenosine deaminase-deficient severe combined immunodeficiency disease (ADA-SCID) is an
inherited defect that results in the accumulation of enzyme substrates, such as adenosine, 2′-deoxyadenosine and deoxyribonucleotides (dAXP) leading to severe lymphopenia with absence of cellular and humoral immunity and recurrent, severe infections. High adenosine levels block the differentiation of thymocytes, induce thymic hypoplasia, and lead to apoptosis resulting in T, B, and NK depletion. Delayed and late onset forms have a wide spectrum of manifestations mostly involving immunological and autoimmune system (i.e., hemolytic anemia and immune thrombocytopenia) as the most severe manifestation (2). Since ADA gene is ubiquitously expressed, non-immunological alterations have been described frequently in ADA-deficient patients involving liver, kidney, bone, and central nervous system (3–6).

BACKGROUND

Eight cases of lymphoma have been reported to date in ADA-SCID patients, and half of them are EBV associated (7–13). Herein, we present the first case of a fatal EBV-associated plasmablastic lymphoma, which developed in an 18-year-old ADA-SCID girl, after enzyme replacement therapy (ERT) and multiple infusions of genetically modified T cells. The patient was diagnosed with ADA deficiency at 3 months of age due to pneumonia and failure to thrive (14). PEG-ADA was started with partial benefit on immune functions and clinical conditions but the lymphocyte count remained low (450–650/μL with 200/μL T cells). No matched bone marrow (BM) donor was available. Between 1 and 5 years of age, she was treated with repeated infusions of autologous peripheral blood (PB) T lymphocytes transduced ex vivo with a gammaretroviral vector encoding ADA (14) (NCT00599781, GIADAl). The patient also received a small amount of autologous BM cells transduced with a similar gammaretroviral vector (differing only at a restriction enzyme site) without any conditioning, after which there was no evidence of engraftment. PEG-ADA was reduced until complete discontinuation to favor the expansion of gene corrected cells (14). Despite the improvement of T cell count and functions with evidence of antibody responses to neoantigens, ERT was restarted at a low dose due to the suboptimal systemic detoxification, maintained at 11.2–12.5 U/kg/week i.m. and continued for further 16 years. The patient experienced mainly self-limited upper respiratory tract infections and autoimmune hemolytic anemia at the age of
6 years, which was treated with high-dose methylprednisolone (15 mg/kg i.v.) followed by prednisone 2 mg/kg/die p.o. which was slowly tapered and eventually stopped 1 year after onset. A mild pulmonary restrictive syndrome with bronchiectasis and arterial hypertension were controlled with specific therapies. At the age of 17, lymphocyte and T cell counts were 800 and 600/µL, respectively. Proliferative responses to mitogens were normal, while responses to antigens (candida and alloantigens) were reduced. The TCR Vbeta repertoire by flow cytometry was polyclonal with two Vbeta families reduced. dAXP toxic metabolites were 6 nmol/mL (0.46%) on PB (normal range: <1%) (10) EBV serology and search for EBV sequence (EBV PCR) were negative.

One year later the patient was hospitalized in a local hospital due to persistent fever, multiple lymphadenopathies and bilateral periorbital edema with intense conjunctival hyperemia, unresponsive to i.v. antibiotics. At admission to our Unit, total body positron emission tomography–computed tomography showed diffuse lymphadenopathies (cervical, spinal-accessorial, supraclavicular, axillary, retropectoral, tonsillar, upper mediastinal, and right paratracheal) and splenomegaly (Figure 1). Interstitial lung involvement accompanied by pleural effusion resulted in respiratory impairment, requiring oxygen supplementation. Brain MRI detected severe edema of pericortical tissue with exophthalmons and lymphoid hyperplasia. Blood tests revealed high plasma EBV DNA load (10 million copies/mL) and elevated anti-VCA EBV IgG with absence of anti-VCA IgM, anti-EBV early antigen and anti-EBV nuclear antigen antibodies. An Ig kappa monoclonal component (10 g/L) was present. Cervical lymphadenectomy and BM examination were performed, and methylprednisolone (1 mg/kg/daily) and anti-CD20 (rituximab 375 mg/m² in two doses) were started before pathological diagnosis was confirmed. Histopathological examination showed an EBV-related plasmablastic B-cell lymphoma (Figure 2). Lymphoma cells displayed a high proliferation index (>90%), were monoclonal for kappa light chain and expressed plasma cell-associated markers such as CD138, CD30, and MUM-1. In addition, these elements were positive for PAX-5 and BCL2 as well as partially positive (40% of cells) for CD20. The EBV marker LMP-1 was present. On the other hand, neoplastic elements scored negative for CD10, CD5, CD4, CD8, BCL6, and CD56. HHV8 was also negative. A minor component of mature-looking plasma cells sharing the same light chain restriction with large neoplastic cells was present at the edge of the lesion, as reported (15). BM evaluation showed reactive dyshematopoiesis with slight increase of plasma cells, which were monoclonal for kappa light chain.

The disease was classified as stage IV B E s. Therapy consisted of continued rituximab weekly infusions and a cycle of APO (adriamycin, vincristine, and prednisone) with no response. Accordingly, cyclophosphamide (300 mg/m² BID for 3 days) and dexamethasone were started. Twelve days after the initiation of chemotherapy, the patient died for a hemorrhagic alveolitis eventually causing worsening respiratory failure, refractory to continuous positive airway pressure and biphasic positive airway pressure mechanical ventilation.

To investigate the potential relationship with PB gene therapy, T cells and B cells were purified from BM, PB, and lymph node, and vector transduction measured by quantitative PCR (14). T cells were highly positive for the vector (BM: >100%; PB: >100%; lymph node: 96.1%) in line with previous follow-up analyses. By contrast, B cells showed low vector signal (BM: 0.43%; PB: 3.1%; lymph node: 6.1%), a level compatible with contamination from T cells, as sample purity was <90% after purification. These data rule out the possibility that the lymphoproliferative event originated from the infused transduced cells.

**DISCUSSION**

The most frequently reported histotype in primary immune deficiencies is diffuse large B-cell lymphoma, which mostly occurs in extra nodal sites (16). Nine cases of lymphoma have been described in ADA-SCID patients, including the present case (Table 1). Of these, five were related to EBV infection (7, 10, 11) with two arising in the lung (10) and the brain (11), respectively, while another was described as a Hodgkin lymphoma (10). An EBV-negative Burkitt’s lymphoma has also been described (12). Overall, six of nine patients developed a malignant disease more than 3 years after the start of PEG-ADA (range 3–17 years) (Table 1). In three patients, alternative treatment was attempted...
| Reference            | ADA mutation          | PEG-ADA | HSCT for ADA-SCID | Lymphoma type                                                                 | Organs involved                                   | EBV related | Age at onset | Treatments for lymphoma | Outcome                        |
|----------------------|-----------------------|---------|------------------|-------------------------------------------------------------------------------|--------------------------------------------------|-------------|---------------|--------------------------|--------------------------------|
| Kapoor (7)           | nk                    | No      | Second haplo T depleted, no conditioning, poor engraftment (only T cells), and donor EBV positive | B cell of host origin, 85% k chain—50% delta chain—90% μ chain | Liver, spleen, CNS, gut, lung, and BM              | Yes         | 1 year after I HSCT | nk                       | Dead 1 week after lymphoma onset |
| Ratech et al. (8)    | nk                    | Yes     | No               | Diffuse large cell immunoblastic plasmacytid type NHL (MALT). Monoclonal IgA, lambda | Gut, spleen, nodes, liver, lung, kidney, meninges, and adrenal gland | nk          | nk            | nk                       | Died at 4 years                |
| Hirschhorn et al. (9)| E217K; exon 1–5 deletion | No      | Haplo-HSCT       | rik                                                                           | nk                                                | nk          | 1.5 years after HSCT | 2 HSCT (haplo)              | Dead                           |
| Hershfield (10)      | nk                    | Yes for 13 years | No               | Hodgkin lymphoma                                                                  | rik                                               | Yes         | 13 years after starting PEG-ADA | HSCT (CB)                     | Died at 16 years                |
| Hershfield (10)      | nk                    | Yes for 10 years | No               | nk                                                                            | Pulmonary nodule                                   | Yes         | 8 years after starting PEG-ADA | Rituximab; HSCT (MUD) at 10 years | Died of viral disease 1 month after HSCT |
| Kaufman et al. (11)  | A83D; Exon5 splice donor site c.573 + 1G>A | Yes for 10 years | No               | B large cell type. Immunoblastic and plasmacytid features. BCL6 neg. Deletion in 1p36, 19q13, and 10q23 | CNS                                               | Yes         | 10 years | DXM + phenytoin; COP + APO + 6-MP; MTX | Dead                           |
| Husain et al. (12)   | Q3X (h)               | Yes for 14 years | No               | Burkitt's lymphoma. CD20 and CD20q positive Aberrant co-expression T marker CD43 | Right iliac-ischial bone                           | No          | 15 years      | Chemotherapy not specified | Complete remission 20 months after diagnosis |
| Genel (13)           | W272X (h)             | Yes for 3 years | No               | Diffuse large B cell lymphoma NHL                                                | Multiple pulmonary nodules and splenic mass       | nk          | 3 years       | Chemotherapy (BFM 2004 protocol) | Dead                           |
| Current patient      | 462delG (h)           | Yes for 17 years | No               | Plasmablastic B-cell lymphoma with plasmacytid features. CD138, MUM-1, kappa light chain monoclonal, CD20 partially positive | Nodes, lungs, periocular, spleen, and BM          | Yes         | 18 years      | Rituximab; APO; and cyclophosphamide + dexamethasone | Dead                           |

**Notes:**
- HSCT, hematopoietic stem cell transplantation; EBV, Epstein–Barr virus; nk, not known; NHL, non-Hodgkin lymphoma; h, homozygous; Haplo, haploidentical; CB, cord blood; MUD, matched unrelated donor; CNS, central nervous system; BM, bone marrow; COP, cyclophosphamide, vincristine, and prednisone; APO, doxorubicin, vincristine, and prednisone; 6-MP, 6-mercaptopurine; ADA-SCID, adenosine deaminase-deficient severe combined immunodeficiency disease.
- *This patient is the brother of the one described in Hirschhorn et al. (9).*
before lymphoma onset, including haploidentical hematopoietic stem cell transplantation (HSCT) \((n = 2)\) and PB T-cell gene therapy. Unfortunately, all patients died despite rescue attempts with several lines of treatments, with the exception of a Burkitt’s hip lymphoma that persisted in complete remission after 20 months from the onset of the malignant disease (12). According to data available in literature seven of nine patients received chemotherapy to cure lymphoma, mostly based on high dose of steroids (prednisone and dexamethasone), anti-mitotic vinca alkaloids (i.e., vincristine), anthracyclines (i.e., doxorubicin), alkylating agents (i.e., cyclophosphamide). Three out of ten patients underwent HSCT after lymphoma, a patient two consecutive haplo-HSCT, and the last two from cord blood and matched unrelated donor, respectively. Unfortunately, all of them (3/3) had a fatal exitus.

To the best of our knowledge, this is the first report of a plasmablastic lymphoma in an ADA-SCID patient. Lymphoma in patients with primary immune deficiency is frequently EBV associated (16). EBV infection indeed seems to play an important role on lymphoproliferative disorder prognosis more than histology or gene rearrangements (16). Moreover, dysregulated secretion of IL-6 has a pivotal role in lymphoproliferative disorders in an autocrine and paracrine cytokine stimulated manner, indeed, it contributes to the development of the auto-maintenance and neoplastic growth of EBV-immortalized B cells (8, 17).

The pathogenesis of lymphomas in ADA-SCID patients remains still unclear. The lack of ADA would be expected to decrease the oncogenic risk since ADA inhibitors have been used for the treatment of lymphomas (18) and the accumulation of adenosine and purine metabolites in ADA-deficient patients leads to increased apoptosis in T and B cells (19). Since all patients described here were either under PEG-ADA treatment or received HSCT, one can speculate that in these patients adenosine metabolites were adequately detoxified. It would be also interesting to investigate whether lymphoma cells spontaneously reverted the ADA mutation, as observed in selected cases of ADA-SCID patients (20). At present, the most likely explanation remains a lack of appropriate immune surveillance similarly to other primary immune deficiencies.

The B-cell clonality identified in our patient by PCR, both on lymph node and on BM, has been associated with poor prognosis, confirming the negative predictive role of this feature previously suggested in a small cohort of patients with lymphoproliferative disorders (16).

Our patient continued long-term ERT since an HLA-identical donor was not available and data of overall survival after matched unrelated or alternative donors (i.e., haploidentical) were not encouraging at that time (66 and 43%, respectively) (21). ERT often leads to a transient improvement of the immune function and clinical parameters, including growth (22, 23), but a gradual immunological decline is actually observed within a few years of treatment (23–26). Our patient also received multiple infusions of genetically corrected T cells and presented a T-cell compartment mainly represented by transduced cells. It is likely that, despite being polyclonal, the T-cell repertoire of the transduced T cells, which were \textit{ex vivo} cultured, was not sufficiently broad to survey and control the B cell transformation induced by the EBV infection. It is also possible that defective functions of other untransduced cell types, such as NK cells, could have contributed to the impaired immune response to EBV. It will be important to continue the strict monitoring of ADA-SCID patients on long-term ERT, including those who received infusions of gene corrected T cells (27–29).

On the other hand, retroviral vector GT with autologous CD34+ cells transduced with ADA has emerged as a safe and efficacious therapeutic strategy for patients lacking HLA-identical sibling donor (26, 30–33). Noteworthy, in comparison with clinical trials conducted on other primary immunodeficiencies (SCIDX1, CGD, and WAS), no lymphoproliferative disorders or aberrant clonal expansion have been observed in more than 40 patients treated worldwide with an available follow-up of more than one decade in some of them (34).

**CONCLUDING REMARKS**

These observations underline the importance of defining a potential lifelong effective treatment for these patients as early as possible. Attending physicians must be aware that the delay of a definitive treatment could expose these fragile patients to multiple severe complications, including aggressive lymphoproliferative disorders.

**ETHICS STATEMENT**

The study was performed in accordance with the Declaration of Helsinki. The patient was enrolled in a clinical trial approved by the San Raffaele Ethical Committee (NCT00599781). Written informed consent was obtained from parents for treatment, biological sample collection, and data publication.

**AUTHOR CONTRIBUTIONS**

M.M., Andrea A., M.P., R.P, F.B., F.G., F.F., M.F., I.B., F.D., R.N., M.C., M.G.R., C.D., J.P., F.C., M.P.C, Alessandro A. participated to clinical care of the patient and related clinical data. M.M. and Alessandro A. designed the study, analyzed results and wrote the paper.

**ACKNOWLEDGMENTS**

The study was supported by grants of the Italian Ministero della Salute (Programma di rete, NET-2011-02350069), the European Commission (ERARE-3-JTC 2015 EUROCID), and Fondazione Telethon. IB is supported by the Italian Ministero della Salute (GR-2011-02346985). The authors are grateful all medical and nursing staff of the TIGET Pediatric Clinical Research Unit and the Pediatric Immunohematology and Bone Marrow Transplant Unit; L. Castagnaro, G. Tomaselli, and all TCTO personnel for clinical trial management and support.
REFERENCES

1. Oertel SH, Riess H. Immuno-surveillance, immunodeficiency and lymphoproliferations. Recent Results Cancer Res (2002) 159:1–8. doi:10.1007/978-3-642-09522-1_1
2. Sauer AV, Brigida I, Carriglio N, Aiuti A. Autoimmune dysregulation and purine metabolism in adenosine deaminase deficiency. Front Immunol (2012) 3:265. doi:10.3389/fimmu.2012.00265
3. Hirschhorn R, Candotti F. Immunodeficiency due to defects of purine metabolism. In: Ochs HD, Smith CIE, Puck JM, editors. Primary Immunodeficiency Diseases. Oxford: Oxford University Press (2006). p. 169–96.
4. Aiuti A, Picca F, Cattaneo F, Bordignon C, Roncarolo MG. Gene therapy for adenosine deaminase deficiency. Curr Opin Allergy Clin Immunol (2003) 3:461–6. doi:10.1097/01030832-200312000-00007
5. Honig M, Albert MH, Schulz A, Sparber-Sauer M, Schutz C, Belohradsky B, et al. Patients with adenosine deaminase deficiency surviving after hematopoietic stem cell transplantation are at high risk of CNS complications. Blood (2007) 109:3595–602. doi:10.1182/blood-2006-07-034678
6. Sauer AV, Hernandez RJ, Fumagalli F, Bianchi V, Poliani PL, Dallatomasina C, et al. Alterations in the brain adenosine metabolism cause behavioral and neurological impairment in ADA-deficient mice and patients. Sci Rep (2017) 7:40136. doi:10.1038/srep40136
7. Kapoor N. Lymphoma in a patient with severe combined immunodeficiency. Sci Transl Med (2014) 6:242-352-2_1
8. Ratech H, Hirschhorn R, Greco MA. Pathologic findings in adenosine deaminase deficiency. Front Immunol (2012) 3:265. doi:10.3389/fimmu.2012.00265
9. Migliavacca et al. First Onset of Plasmablastic Lymphoma in ADA-SCID

Conflict of Interest Statement: Alessandro A is the Principal investigator of gene therapy studies sponsored by GlaxoSmithKline (GSK), which holds the licence for the medicinal product based on autologous CD34+ cell gene therapy for ADA-SCID. All other authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Migliavacca, Assanelli, Ponzoni, Pajno, Berzaghi, Giglio, Ferrua, Frittioli, Brigida, Dionisio, Nicolleti, Casaghi, Roncaro, Doglioni, Peccatori, Ciceri, Cicalese and Aiuti. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

First Onset of Plasmablastic Lymphoma in ADA-SCID

Frontiers in Immunology | www.frontiersin.org 6 February 2018 | Volume 9 | Article 113

10. Sauer AV, Brigida I, Carriglio N, Aiuti A. Autoimmune dysregulation and purine metabolism in adenosine deaminase deficiency. Front Immunol (2012) 3:265. doi:10.3389/fimmu.2012.00265
11. Hirschhorn R, Candotti F. Immunodeficiency due to defects of purine metabolism. In: Ochs HD, Smith CIE, Puck JM, editors. Primary Immunodeficiency Diseases. Oxford: Oxford University Press (2006). p. 169–96.
12. Aiuti A, Picca F, Cattaneo F, Bordignon C, Roncarolo MG. Gene therapy for adenosine deaminase deficiency. Curr Opin Allergy Clin Immunol (2003) 3:461–6. doi:10.1097/01030832-200312000-00007
13. Honig M, Albert MH, Schulz A, Sparber-Sauer M, Schutz C, Belohradsky B, et al. Patients with adenosine deaminase deficiency surviving after hematopoietic stem cell transplantation are at high risk of CNS complications. Blood (2007) 109:3595–602. doi:10.1182/blood-2006-07-034678
14. Sauer AV, Hernandez RJ, Fumagalli F, Bianchi V, Poliani PL, Dallatomasina C, et al. Alterations in the brain adenosine metabolism cause behavioral and neurological impairment in ADA-deficient mice and patients. Sci Rep (2017) 7:40136. doi:10.1038/srep40136
15. Kapoor N. Lymphoma in a patient with severe combined immunodeficiency with adenosine deaminase deficiency, following unnoticed engraftment of histocompatible T cell-depleted bone marrow. J Pediatr (1986) 108(3):435–48. doi:10.1016/S0022-3476(86)80892-7
16. Ratech H, Hirschhorn R, Greco MA. Pathologic findings in adenosine deaminase-deficient combined immunodeficiency. II. Thymus, spleen, lymph node, and gastrointestinal tract lymphoid tissue alterations. Am J Pathol (1989) 135(6):1145–56.
17. Hirschhorn R, Nicknam MN, Eng F, Yang DR, Borkowsky W. Novel deletion and a new missense mutation (Glu217Lys) at the catalytic site in two adenosine deaminase alleles of a patient with neonatal onset adenosine deaminase-severe combined immunodeficiency. J Immunol (1992) 149(9):3107–12.
18. Hershfield MS. Combined Immune Deficiencies due to Purine Enzyme Defects: Steihm ER, Ochs HD, Winkelstein JA, editors. Immune Disorders in Infants and Children. Philadelphia, PA: WB Saunders (2004). p. 480–504.
19. Kaufman DA, Hershfield MS, Bocchini JA, Moissidis II, Jeroudi M, Bahna SL. Cerebral lymphoma in an adenosine deaminase deficient patient with severe combined immunodeficiency receiving polyethylene glycol conjugated adenosine deaminase. Pediatrics (2005) 116(6):e876–9. doi:10.1542/peds.2005-1068
20. Husain M, et al. Burkitt’s lymphoma in a patient with adenosine deaminase deficiency severe combined immunodeficiency treated with polyethylene glycol-adenosine deaminase. J Pediatr (2007) 151:93–5. doi:10.1016/j.jpeds.2007.03.059
21. Genel F. Adenosine deaminase-deficient severe combined immunodeficiency and diffuse large B-cell lymphoma. Pediatr Allergy Immunol Pulmonol (2015) 28(2):138–42. doi:10.1089/ped.2014.0478
22. Aiuti A. Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement. Nat Med (2002) 8(5):423–5. doi:10.1038/nm0502-423
23. Stein H, Harris NL, Campo E, Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Hematopoietic and Lymphoid Tissue. Lyon: IARC (2008).
24. Canioni D,jabado N, MacIntyre E, Patey N, Emile JF, Brousse N. Lymphoproliferative disorders in children with primary immunodeficiencies: immunological status may be more predictive of the outcome than other criteria. Histopathology (2001) 38(2):146–59. doi:10.1046/j.1365-2559.2001.01039.x
25. Ohga S, Nomura A, Takada H, Harra T. Immunological aspects of Epstein-Barr virus infection. Crit Rev Oncol Hematol (2002) 44(3):203–15. doi:10.1016/S1040-8428(02)00112-9
26. Argnani L, Broccali A, Zinzani PL. Cutaneous T-cell lymphomas: focusing on novel agents in relapsed and refractory disease. Cancer Treat Rev (2017) 61:61–9. doi:10.1016/j.ctrv.2017.10.007
27. Sauer AV, Di Lorenzo B, Carriglio N, Aiuti A. Progress in gene therapy for primary immunodeficiencies using lentiviral vectors. Curr Opin Allergy Clin Immunol (2014) 14(6):527–34. doi:10.1097/ACI.0000000000000114